This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
5 Small Drug Stocks to Buy as Innovation Reaches Peak
by Kinjel Shah
Innovation is at its peak for the Zacks Medical-Drugs industry. CORT, AMRX, BVS, FHTX, and AKBA may prove to be good additions to one's portfolio.
Is Sensus Healthcare (SRTS) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Sensus Healthcare, Inc. (SRTS) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.
Compared to Estimates, Amneal (AMRX) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Amneal (AMRX) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
AMNEAL PHARMACEUTICALS, INC. (AMRX) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Amneal (AMRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Amneal Pharmaceuticals (AMRX) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Amneal (AMRX) delivered earnings and revenue surprises of 14.29% and 6.75%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
4D Molecular Therapeutics (FDMT) delivered earnings and revenue surprises of 12.50% and 99.74%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
MediWound (MDWD) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
MediWound (MDWD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street's Insights Into Key Metrics Ahead of Amneal (AMRX) Q2 Earnings
by Zacks Equity Research
Get a deeper insight into the potential performance of Amneal (AMRX) for the quarter ended June 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Zoetis (ZTS) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Zoetis (ZTS) delivered earnings and revenue surprises of 4.70% and 2.53%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Bausch Health (BHC) Q2 Earnings In Line, Xifaxan Boosts Sales
by Zacks Equity Research
Bausch Health's (BHC) second-quarter adjusted earnings meet estimates while sales top the same, fueled by growth in Xifaxan sales.
Earnings Preview: Amneal Pharmaceuticals (AMRX) Q2 Earnings Expected to Decline
by Zacks Equity Research
Amneal (AMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amneal Pharmaceuticals (AMRX) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Amneal Pharmaceuticals (AMRX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Are Medical Stocks Lagging Amneal Pharmaceuticals (AMRX) This Year?
by Zacks Equity Research
Here is how Amneal Pharmaceuticals (AMRX) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.
Amneal (AMRX) Is Attractively Priced Despite Fast-paced Momentum
by Zacks Equity Research
Amneal (AMRX) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
Bausch (BHC) Q1 Earnings and Revenues Miss, Shares Fall
by Zacks Equity Research
Bausch's (BHC) first-quarter earnings and sales miss their respective estimates. Its shares fall in response to the results.
Amneal (AMRX) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
Although the revenue and EPS for Amneal (AMRX) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Amneal Pharmaceuticals (AMRX) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Amneal (AMRX) delivered earnings and revenue surprises of 55.56% and 5.80%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Amneal (AMRX): Can Its 12.0% Jump Turn into More Strength?
by Zacks Equity Research
Amneal (AMRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Bausch (BHC) Starts Litigation Against Amneal for Xifaxan
by Zacks Equity Research
Bausch (BHC) initiates litigation against Amneal Pharmaceuticals and its subsidiaries over a generic version of its lead drug Xifaxan.
Amneal (AMRX) Stock Jumps 7.3%: Will It Continue to Soar?
by Zacks Equity Research
Amneal (AMRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Amneal (AMRX) Reports Q4 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Amneal (AMRX) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Amneal Pharmaceuticals (AMRX) Beats Q4 Earnings Estimates
by Zacks Equity Research
Amneal (AMRX) delivered earnings and revenue surprises of 100% and 2.17%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Countdown to Amneal (AMRX) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for Amneal (AMRX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023.
Amneal (AMRX) Shows Fast-paced Momentum But Is Still a Bargain Stock
by Zacks Equity Research
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Amneal (AMRX) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Aquestive Therapeutics (AQST) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.